Many women experience hormonal changes during perimenopause and menopause that can affect metabolism, body composition, energy levels, and fat distribution
The first step in management of non-emergency hyperkalemia is to exclude pseudohyperkalemia (i.e., false elevations of potassium levels due to issues such as hemolysis)
The most well-known examples, apart from pioglitazone, are fenofibrate, pemafibrate, seladelpar, elafibranor and lanifibranor, which have been studied in various trials regarding their effect on liver inflammation and fibrosis, without particular success, with the exception of lanifibranor, a pan-PPAR agonist, which was shown in a phase 2b RCT (NATIVE-NCT03008070) to improve ballooning and inflammation, without worsening of fibrosis
[19] [20] When to Speak with Your GP About Stopping GLP-1 Several situations warrant a conversation with your GP or prescribing clinician about discontinuing GLP-1 receptor agonist therapy
Both can be safe if prescribed and filled legally, but access and pricing differ
Ozempic (semaglutide) has a longer safety record and wider availability
